Cabio End Period Cash Flow vs Change To Netincome Analysis

688089 Stock

19.37 0.31 1.58%

Cabio Biotech financial indicator trend analysis is way more than just evaluating Cabio Biotech Wuhan prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cabio Biotech Wuhan is a good investment. Please check the relationship between Cabio Biotech End Period Cash Flow and its Change To Netincome accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cabio Biotech Wuhan. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

End Period Cash Flow vs Change To Netincome

End Period Cash Flow vs Change To Netincome Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cabio Biotech Wuhan End Period Cash Flow account and Change To Netincome. At this time, the significance of the direction appears to have no relationship.

The correlation between Cabio Biotech's End Period Cash Flow and Change To Netincome is 0.06. Overlapping area represents the amount of variation of End Period Cash Flow that can explain the historical movement of Change To Netincome in the same time period over historical financial statements of Cabio Biotech Wuhan, assuming nothing else is changed. The correlation between historical values of Cabio Biotech's End Period Cash Flow and Change To Netincome is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which End Period Cash Flow of Cabio Biotech Wuhan are associated (or correlated) with its Change To Netincome. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change To Netincome has no effect on the direction of End Period Cash Flow i.e., Cabio Biotech's End Period Cash Flow and Change To Netincome go up and down completely randomly.

Correlation Coefficient

0.06

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

End Period Cash Flow

Change To Netincome

Most indicators from Cabio Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cabio Biotech Wuhan current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cabio Biotech Wuhan. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

The current year's Tax Provision is expected to grow to about 17.8 M. The current year's Selling General Administrative is expected to grow to about 33.6 M

	2022	2023	2024	2025 (projected)
Gross Profit	182.7M	188.2M	216.4M	169.2M
Total Revenue	433.4M	443.8M	510.4M	353.1M

Gross Profit Total Revenue

Cabio Biotech fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Net Receivables	Non Current Liabilities Total	Inventory	Other Current Assets	Total Liab	Short Long Term Debt	Total Current Assets	Intangible Assets	Other Current Liab	Common Stock Shares Outstanding	Net Invested Capital	Net Working Capital	Capital Stock	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Other Assets	Other Stockholder Equity
Total Assets		0.59	1.0	0.98	0.81	0.73	0.75	0.71	0.96	-0.76	0.16	0.82	0.58	-0.58	0.89	0.29	0.5	0.89	1.0	0.84	0.89	-0.8	0.83	0.78	0.71	-0.89
Total Current Liabilities	0.59		0.54	0.54	0.84	0.07	0.69	0.23	0.63	-0.55	0.49	0.67	1.0	0.17	0.28	0.75	0.52	0.56	0.56	0.18	0.56	-0.83	0.65	0.79	0.3	-0.6
Total Stockholder Equity	1.0	0.54		0.98	0.78	0.76	0.73	0.72	0.96	-0.75	0.12	0.8	0.53	-0.62	0.91	0.24	0.48	0.88	1.0	0.86	0.88	-0.77	0.81	0.75	0.72	-0.89
Retained Earnings	0.98	0.54	0.98		0.79	0.69	0.76	0.79	0.95	-0.81	0.13	0.82	0.53	-0.66	0.86	0.27	0.46	0.88	0.98	0.8	0.88	-0.8	0.84	0.77	0.78	-0.91
Accounts Payable	0.81	0.84	0.78	0.79		0.38	0.91	0.45	0.83	-0.84	0.31	0.93	0.83	-0.27	0.58	0.58	0.47	0.75	0.8	0.5	0.76	-0.93	0.85	0.86	0.54	-0.83
Cash	0.73	0.07	0.76	0.69	0.38		0.25	0.57	0.59	-0.38	-0.48	0.37	0.06	-0.65	0.96	-0.41	0.59	0.42	0.75	0.98	0.42	-0.22	0.35	0.14	0.58	-0.61
Non Current Assets Total	0.75	0.69	0.73	0.76	0.91	0.25		0.5	0.8	-0.81	0.52	0.99	0.68	-0.26	0.48	0.63	0.11	0.84	0.76	0.42	0.86	-0.93	0.93	0.9	0.58	-0.8
Non Currrent Assets Other	0.71	0.23	0.72	0.79	0.45	0.57	0.5		0.6	-0.44	0.02	0.51	0.22	-0.53	0.66	-0.07	0.36	0.57	0.72	0.65	0.57	-0.55	0.63	0.44	0.98	-0.77
Net Receivables	0.96	0.63	0.96	0.95	0.83	0.59	0.8	0.6		-0.85	0.28	0.86	0.62	-0.55	0.79	0.44	0.36	0.94	0.96	0.72	0.94	-0.85	0.84	0.86	0.59	-0.8
Non Current Liabilities Total	-0.76	-0.55	-0.75	-0.81	-0.84	-0.38	-0.81	-0.44	-0.85		-0.16	-0.85	-0.53	0.61	-0.58	-0.47	-0.25	-0.76	-0.75	-0.5	-0.77	0.8	-0.77	-0.78	-0.46	0.69
Inventory	0.16	0.49	0.12	0.13	0.31	-0.48	0.52	0.02	0.28	-0.16		0.43	0.5	0.36	-0.26	0.85	-0.41	0.53	0.14	-0.31	0.52	-0.54	0.51	0.67	0.0	-0.16
Other Current Assets	0.82	0.67	0.8	0.82	0.93	0.37	0.99	0.51	0.86	-0.85	0.43		0.66	-0.35	0.58	0.57	0.18	0.87	0.83	0.53	0.89	-0.92	0.93	0.89	0.58	-0.83
Total Liab	0.58	1.0	0.53	0.53	0.83	0.06	0.68	0.22	0.62	-0.53	0.5	0.66		0.19	0.27	0.75	0.52	0.55	0.55	0.17	0.55	-0.83	0.65	0.79	0.29	-0.6
Short Long Term Debt	-0.58	0.17	-0.62	-0.66	-0.27	-0.65	-0.26	-0.53	-0.55	0.61	0.36	-0.35	0.19		-0.68	0.23	-0.17	-0.47	-0.58	-0.67	-0.47	0.22	-0.35	-0.23	-0.47	0.45
Total Current Assets	0.89	0.28	0.91	0.86	0.58	0.96	0.48	0.66	0.79	-0.58	-0.26	0.58	0.27	-0.68		-0.16	0.59	0.64	0.9	0.99	0.65	-0.47	0.57	0.41	0.67	-0.77
Intangible Assets	0.29	0.75	0.24	0.27	0.58	-0.41	0.63	-0.07	0.44	-0.47	0.85	0.57	0.75	0.23	-0.16		-0.12	0.56	0.25	-0.26	0.56	-0.7	0.57	0.81	-0.05	-0.28
Other Current Liab	0.5	0.52	0.48	0.46	0.47	0.59	0.11	0.36	0.36	-0.25	-0.41	0.18	0.52	-0.17	0.59	-0.12		0.1	0.48	0.53	0.09	-0.3	0.19	0.14	0.42	-0.51
Common Stock Shares Outstanding	0.89	0.56	0.88	0.88	0.75	0.42	0.84	0.57	0.94	-0.76	0.53	0.87	0.55	-0.47	0.64	0.56	0.1		0.89	0.58	1.0	-0.84	0.9	0.91	0.55	-0.77
Net Invested Capital	1.0	0.56	1.0	0.98	0.8	0.75	0.76	0.72	0.96	-0.75	0.14	0.83	0.55	-0.58	0.9	0.25	0.48	0.89		0.86	0.89	-0.78	0.83	0.76	0.72	-0.9
Net Working Capital	0.84	0.18	0.86	0.8	0.5	0.98	0.42	0.65	0.72	-0.5	-0.31	0.53	0.17	-0.67	0.99	-0.26	0.53	0.58	0.86		0.59	-0.38	0.51	0.32	0.66	-0.72
Capital Stock	0.89	0.56	0.88	0.88	0.76	0.42	0.86	0.57	0.94	-0.77	0.52	0.89	0.55	-0.47	0.65	0.56	0.09	1.0	0.89	0.59		-0.84	0.91	0.91	0.55	-0.78
Other Liab	-0.8	-0.83	-0.77	-0.8	-0.93	-0.22	-0.93	-0.55	-0.85	0.8	-0.54	-0.92	-0.83	0.22	-0.47	-0.7	-0.3	-0.84	-0.78	-0.38	-0.84		-0.89	-0.95	-0.6	0.79
Net Tangible Assets	0.83	0.65	0.81	0.84	0.85	0.35	0.93	0.63	0.84	-0.77	0.51	0.93	0.65	-0.35	0.57	0.57	0.19	0.9	0.83	0.51	0.91	-0.89		0.88	0.67	-0.83
Property Plant And Equipment Net	0.78	0.79	0.75	0.77	0.86	0.14	0.9	0.44	0.86	-0.78	0.67	0.89	0.79	-0.23	0.41	0.81	0.14	0.91	0.76	0.32	0.91	-0.95	0.88		0.45	-0.72
Other Assets	0.71	0.3	0.72	0.78	0.54	0.58	0.58	0.98	0.59	-0.46	0.0	0.58	0.29	-0.47	0.67	-0.05	0.42	0.55	0.72	0.66	0.55	-0.6	0.67	0.45		-0.82
Other Stockholder Equity	-0.89	-0.6	-0.89	-0.91	-0.83	-0.61	-0.8	-0.77	-0.8	0.69	-0.16	-0.83	-0.6	0.45	-0.77	-0.28	-0.51	-0.77	-0.9	-0.72	-0.78	0.79	-0.83	-0.72	-0.82

Click cells to compare fundamentals

Cabio Biotech Account Relationship Matchups

Cabio Biotech fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	1.4B	1.4B	1.6B	1.6B	1.9B	1.2B
Total Current Liabilities	52.3M	60.0M	180.4M	112.4M	129.3M	82.2M
Total Stockholder Equity	1.3B	1.4B	1.4B	1.5B	1.7B	1.1B
Retained Earnings	327.9M	416.9M	375.4M	421.3M	484.5M	291.8M
Accounts Payable	24.5M	31.4M	107.3M	70.9M	81.5M	85.6M
Cash	847.3M	664.5M	494.3M	239.7M	275.6M	458.3M
Non Current Assets Total	259.7M	453.6M	703.5M	902.7M	1.0B	1.1B
Non Currrent Assets Other	23.6M	74.9M	17.5M	28.2M	32.4M	22.2M
Net Receivables	128.5M	151.1M	189.0M	214.8M	247.0M	149.9M
Non Current Liabilities Total	7.0M	6.7M	5.3M	5.2M	4.7M	5.1M
Inventory	65.5M	74.9M	81.5M	112.6M	129.5M	87.9M
Other Current Assets	20.9M	24.7M	41.8M	51.3M	59.0M	61.9M
Total Liab	59.3M	66.7M	185.8M	117.6M	135.2M	89.2M
Total Current Assets	1.1B	994.9M	907.4M	708.8M	815.1M	790.9M
Intangible Assets	14.5M	13.2M	36.3M	41.1M	47.2M	26.8M
Other Current Liab	10.3M	9.6M	22.6M	270.6K	311.2K	295.6K
Net Invested Capital	1.3B	1.4B	1.5B	1.5B	1.7B	1.2B
Net Working Capital	1.1B	934.9M	726.9M	596.4M	685.8M	779.8M
Property Plant And Equipment Net	149.5M	241.9M	486.0M	643.3M	739.8M	370.6M
Property Plant And Equipment Gross	406.0M	513.7M	486.0M	970.2M	1.1B	610.7M

Currently Active Assets on Macroaxis

MSFT	Microsoft
V	Visa Class A
C	Citigroup
DD	Dupont De Nemours
GM	General Motors

Other Information on Investing in Cabio Stock

Balance Sheet is a snapshot of the financial position of Cabio Biotech Wuhan at a specified time, usually calculated after every quarter, six months, or one year. Cabio Biotech Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Cabio Biotech and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Cabio currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cabio End Period Cash Flow vs Change To Netincome Analysis

End Period Cash Flow vs Change To Netincome

End Period Cash Flow vs Change To Netincome Correlation Analysis

Correlation Coefficient

End Period Cash Flow

Change To Netincome

Cabio Biotech fundamental ratios Correlations

Cabio Biotech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cabio Biotech fundamental ratios Accounts

Currently Active Assets on Macroaxis

Other Information on Investing in Cabio Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Net Invested Capital	+ 1.0	Total Stockholder Equity
Capital Stock	+ 1.0	Common Stock Shares Outstanding
Other Current Assets	+ 0.99	Non Current Assets Total

Property Plant And Equipment Net	- 0.95	Other Liab
Other Liab	- 0.93	Non Current Assets Total
Other Liab	- 0.93	Accounts Payable
Other Liab	- 0.92	Other Current Assets
Other Stockholder Equity	- 0.91	Retained Earnings
Other Stockholder Equity	- 0.9	Net Invested Capital